World Vaccines Market 2012-2022

Date: July 25, 2012
Pages: 199
Price:
US$ 2,635.00
License [?]:
Publisher: Visiongain
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: WB4AEE952F9EN
Leaflet:

Download PDF Leaflet

World Vaccines Market 2012-2022
Report Details

Why the vaccine market can expand - you discover its commercial potential


Where is the vaccines sector heading? Visiongain's report shows you forecasted revenues to 2022. You see data, trends, opportunities and industry prospects.

Our new study investigates vaccines for human beings, letting you assess projected sales at overall world market, submarket, product and national level. Many segments hold growth potential.

Analysis of submarkets and products

In addition to the overall market, you see revenue forecasting of four world-level submarkets to 2022:
  • Paediatric vaccines
  • Influenza vaccines
  • Adult prophylactic vaccines
  • Therapeutic vaccines.
Also, how will 12 leading products and branded groups - including Prevnar-13, Pentacel, Gardasil and Fluzone - perform to 2022? Our investigation shows business research and analysis with sales forecasts and discussions.

What are the prospects in leading regions and countries?

There are many commercial opportunities in developed and developing countries. You discover revenue forecasts to 2022 for eleven national markets:
  • US
  • Japan
  • Germany, France, UK, Spain and Italy (EU5)
  • Brazil, Russia, India and China (BRIC).
New products from 2012 onwards will benefit world, regional and national markets.

Coverage of research and development

What about the R&D pipeline? You see developmental trends there:
  • Paediatric applications
  • Influenza
  • HPV
  • Adult prophylactic agents
  • HIV
  • Pneumococcal products
  • Therapeutic vaccines.
Technology and other progress will change the sector. The report explains.

What issues affect the vaccines industry and market?

Our study lets you assess industry trends and outlooks worldwide from 2012. You see many discussions:
  • Manufacturing, storage, distribution and supply
  • Emerging applications, including cancers
  • Payers and pricing
  • Safety and regulators
  • Technologies - antigens, adjuvants and delivery systems
  • Policy, pandemics and other issues.
Leading companies and revenue prospects

From 2012 to 2022, biopharma companies will increase the industry's revenues. More vaccination of adults and use of therapeutic vaccines in cancer treatment will stimulate the market.

The R&D pipeline is strong. Also, leading brands retain potential. Our report predicts strong growth in the market's revenues from 2012 to 2022.

Our work discusses Sanofi Pasteur, Pfizer, GSK, Merck and other vaccine developers and manufacturers. This decade, many opportunities will arise for companies.

Commercial news, developmental trends and sales forecasting

In the report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), R&D and commercial developments. You receive 91 tables, 63 charts and a research interview.

Eight ways World Vaccines Market 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:
  • Find potential revenues to 2022 for the overall world market and submarkets
  • Discover projected revenues of leading products to 2022
  • See market forecasting to 2022 for US, Japan, Germany, France, UK, Spain and Italy (EU5), Brazil, Russia, India and China (BRIC)
  • Assess companies, discovering activities and outlooks
  • Review R&D pipelines, seeing trends
  • View opinions on the sector, including a research interview
  • Investigate competition and opportunities influencing sales
  • Find out what stimulates and restrains the industry and market.
There you find quantitative and qualitative analyses with independent predictions. You receive information unique to our report, helping you stay informed on business intelligence.

Gain research and analysis for vaccines now

Visiongain's study is for everybody needing industry and market analyses for vaccines. You find data, trends and predictions there. Please order that report now.
1. EXECUTIVE SUMMARY

1.1 Overview of Findings
1.2 Report Contents
1.3 Research and Analysis Methods

2. INTRODUCTION TO THE VACCINES MARKET IN 2012

2.1 A Brief History of Vaccines
2.2 How Vaccines Work: The Immune System and Natural Immunity
  2.2.1 Vaccines Create Artificial Immunity
2.3 Types of Vaccine
  2.3.1 Live, Attenuated Vaccines
  2.3.2 Recombinant Live Vaccines
  2.3.3 Inactivated Vaccines
  2.3.4 Toxoid Vaccines
  2.3.5 Subunit Vaccines
  2.3.6 Conjugate Vaccines
  2.3.7 Recombinant Subunit Vaccines
  2.3.8 DNA Vaccines
  2.3.9 Recombinant Vector Vaccines
  2.3.10 Therapeutic Vaccines

3. WORLD VACCINES MARKET: OVERVIEW 2012-2022

3.1 World Vaccines Market Forecast, 2012-2022
3.2 Market Segmentation, 2012-2022
3.3 Leading Companies in the Market, 2012
  3.3.1 GlaxoSmithKline, 2012
  3.3.2 Sanofi Pasteur, 2012
  3.3.3 Pfizer, 2012
  3.3.4 Merck, 2012
  3.3.5 Novartis, 2012
  3.3.6 Other Vaccine Manufacturers, 2012
3.4 The US, Japan and Other Leading National Markets, 2011-2022
  3.4.1 EU5 National Market Breakdown, 2011-2022
  3.4.2 BRIC National Market Breakdown, 2011-2022

4. PAEDIATRIC VACCINES MARKET, 2012-2022

4.1 Paediatric Vaccines Market Forecast, 2012-2022
4.2 Paediatric Vaccines Market Overview, 2012
  4.2.1 Leading Companies in the Paediatric Vaccines Segment, 2012
  4.2.2 Regional Variations in the Paediatric Vaccines Segment, 2012
  4.2.3 Drivers and Restraints in the Paediatric Vaccines Segment, 2012
4.3 Leading Products in the Paediatric Vaccines Segment, 2012-2022
  4.3.1 Prevnar-13 (Pfizer)
    4.3.1.1 Drivers and Restraints for Prevnar-13, 2012
    4.3.1.2 Market Forecast for Prevnar-13, 2012-2022
  4.3.2 Pentacel/Pediacel/Pentaxim/Others (Sanofi Pasteur)
    4.3.2.1 Drivers and Restraints for Pentacel/Pediacel/Pentaxim/Others, 2012
    4.3.2.2 Market Forecast for Pentacel/Pediacel/Pentaxim/Others, 2012-2022
  4.3.3 Proquad/MMR-II/Varivax (Merck)
    4.3.3.1 Drivers and Restraints for ProQuad/MMR-II/Varivax 2012
    4.3.3.2 Market Forecast for ProQuad/MMR-II/Varivax, 2012-2022
  4.3.4 Infanrix/Pediarix/Others (GlaxoSmithKline)
    4.3.4.1 Drivers and Restraints for Infanrix/Pediarix/Others, 2012
    4.3.4.2 Market Forecast for Infanrix/Pediarix/Others 2012-2022
  4.3.5 RotaTeq (Merck)
    4.3.5.1 Drivers and Restraints for RotaTeq, 2012
    4.3.5.2 Market Forecast for RotaTeq 2012-2022
  4.3.6 Other Paediatric Vaccines
4.4 Paediatric Vaccines Pipeline, 2012
  4.4.1 Bexsero (Novartis)
  4.4.2 Hexaxim (Sanofi Pasteur)
  4.4.3 Menveo Infants (Novartis)
  4.4.4 MenHibrix (GlaxoSmithKline)
  4.4.5 Mosquirix (GlaxoSmithKline)
  4.4.6 V419 (Merck)
  4.4.7 Ixiaro (Intercell)
  4.4.8 Nimenrix (GlaxoSmithKline)
  4.4.9 Quadracel (Sanofi Pasteur)
  4.4.10 V212 (Merck)
  4.4.11 Other Paediatric Vaccine Pipeline Products, 2012
4.5 Segment Revenues by Product, 2012-2022: Summary

5. INFLUENZA VACCINES MARKET, 2012-2022

5.1 Influenza Vaccines Market Forecast, 2012-2022
5.2 Influenza Vaccines Market Overview, 2012
  5.2.1 Leading Companies in the Influenza Vaccines Segment, 2012
  5.2.2 Regional Variations in the Influenza Vaccines Segment, 2012
  5.2.3 Drivers and Restraints in the Influenza Vaccines Segment, 2012
5.3 Leading Products in the Influenza Vaccines Market, 2012
  5.3.1 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others (Sanofi Pasteur)
    5.3.1.1 Drivers and Restraints for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others (Sanofi Pasteur), 2012
    5.3.1.2 Market Forecast for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2012-2022
  5.3.2 Fluarix/Flulaval (GlaxoSmithKline)
    5.3.2.1 Drivers and Restraints for Fluarix/Flulaval, 2012
    5.3.2.2 Market Forecast for Fluarix/Flulaval, 2012
  5.3.3 Other Seasonal Influenza Vaccines, 2012
  5.3.4 Pandemic Influenza Vaccines, 2012
5.4 Influenza Vaccines Pipeline, 2012
5.5 Segment Revenues by Product, 2012-2022: Summary

6. ADULT PROPHYLACTIC VACCINES MARKET, 2012-2022

6.1 Adult Prophylactic Vaccines Market Forecast, 2012-2022
6.2 Adult Prophylactic Vaccines Market Overview, 2012
  6.2.1 Leading Companies in the Adult Prophylactic Vaccines Segment, 2012
  6.2.2 Regional Variations in the Adult Prophylactic Vaccines Segment, 2012
  6.2.3 Drivers and Restraints in the Adult Prophylactic Vaccines Segment, 2012
6.3 Leading Products in the Adult Prophylactic Vaccines Segment, 2012
  6.3.1 Gardasil (Merck)
    6.3.1.1 Drivers and Restraints for Gardasil, 2012
    6.3.1.2 Market Forecast for Gardasil, 2012-2022
  6.3.2 Engerix/Fendrix/Havrix/Twinrix/Ambirix (GlaxoSmithKline)
    6.3.2.1 Drivers and Restraints for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012
    6.3.2.2 Market Forecast for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012-2022
  6.3.3 Cervarix (GlaxoSmithKline)
    6.3.3.1 Drivers and Restraints for Cervarix, 2012
    6.3.3.2 Market Forecast for Cervarix, 2012-2022
  6.3.4 Menactra and Other Meningitis/Pneumonia Vaccines (Sanofi Pasteur)
    6.3.4.1 Drivers and Restraints for Menactra and Other Meningitis/Pneumonia Vaccines, 2012
    6.3.4.2 Market Forecast for Menactra and Other Meningitis/Pneumonia Vaccines, 2012-2022
  6.3.5 Adacel and Other Adult Boosters (Sanofi Pasteur)
    6.3.5.1 Drivers and Restraints for Adacel and Other Adult Boosters, 2012
    6.3.5.2 Market Forecast for Adacel and Other Adult Boosters, 2012-2022
  6.3.6 Other Adult Prophylactic Vaccines
6.4 Adult Prophylactic Vaccines Pipeline, 2012
  6.4.1 GSK1437173A (GlaxoSmithKline)
  6.4.2 BioThrax (Emergent BioSolutions)
  6.4.3 Dengue Fever Vaccine (Sanofi Pasteur)
  6.4.4 Heplisav (Dynavax Technologies)
  6.4.5 V503 (Merck)
  6.4.6 Other Pipeline Adult Prophylactic Vaccines, 2012
6.5 Segment Revenues by Product, 2012-2022: Summary

7. THERAPEUTIC VACCINES MARKET, 2012-2022

7.1 Therapeutic Vaccines Market Forecast, 2012-2022
7.2 Therapeutic Vaccines Market Overview, 2012
  7.2.1 Leading Companies in the Therapeutic Vaccines Segment, 2012
  7.2.2 Regional Variations in the Therapeutic Vaccines Segment, 2012
  7.2.3 Drivers and Restraints in the Therapeutic Vaccines Segment, 2012
7.3 Provenge: Leading Therapeutic Vaccine, 2011
  7.3.1 Drivers and Restraints for Provenge, 2012
  7.3.2 Market Forecast for Provenge, 2012-2022
7.4 Therapeutic Vaccines Pipeline, 2012
  7.4.1 Abagovamab (Menarini)
  7.4.2 MAGE-A3 (GlaxoSmithKline)
  7.4.3 BioVaxID (Biovest International)
  7.4.4 DCVax-Prostate (NorthWest Biotherapeutics)
  7.4.5 GVAX Prostate (Biosante Pharmaceuticals)
  7.4.6 HyperAcute Pancreas (New Look Genetics)
  7.4.7 IMA901 (Immatics Biotechnology)
  7.4.8 Lucanix (Novarx)
  7.4.9 M200 Prophage Cancer Vaccine (Agenus)
  7.4.10 MVax (Avax Technologies)
  7.4.11 Neuvax (Galena Biopharma)
  7.4.12 Polyclonal Antibody Stimulator (Cancer Advances)
  7.4.13 PROSTVAC (Bavarian Nordic)
  7.4.14 Rindopepimut (Celldex Therapeutics)
  7.4.15 Stimuvax (EMD Serono)
  7.4.16 CVac (Prima Biomed)
  7.4.17 Other Therapeutic Cancer Vaccines
  7.4.18 Therapeutic Allergy Vaccines
  7.4.19 Grass Pollen Extract Sublingual Vaccine (Stallergenes)
  7.4.20 Pollinex Quattro (Allergy Therapeutics)
  7.4.21 Ragweed Allergy Vaccine (Greer Laboratories)
  7.4.22 Ragweed Allergy Vaccine and Grass Pollen Allergy Vaccine (ALK Abello)
  7.4.23 Therapeutic Addiction Vaccines
  7.4.24 NicVAX (Nabi Biopharmaceuticals)
  7.4.25 Therapeutic Chronic Infectious Disease Vaccines
  7.4.26 Therapeutic Vaccines for Other Chronic Disease
7.5 Segment Revenues by Product, 2012-2022: Summary

8. INDUSTRY TRENDS, 2012-2022

8.1 Strengths: Vaccines are a Major Ongoing Healthcare Success Story
8.2 Weaknesses: High Costs and Uncertainties in Vaccine Manufacture, Storage and Supply
8.3 Opportunities: Vaccines are Annexing New Therapeutic Areas, and Have Advantages for Market Growth
8.4 Threats: Premium-Priced Vaccines Must Convince Regulators and Payers
8.5 Social: Vaccines Excite Unwarranted Controversy
8.6 Technological: New Antigens, New Adjuvants, New Delivery Systems
8.7 Economic: Rise of the Vaccine-Developing Countries
8.8 Political: Vaccines in National and International Policy

9. RESEARCH INTERVIEW

9.1 Interview with Dr Louis Picker, Associate Director of OHSU's Vaccine and Gene Therapy Institute
  9.1.1 The Basic Challenge of Developing an HIV Vaccine
  9.1.2 Early Interception of HIV Infections via Antibodies
  9.1.3 Early Interception of HIV Infections via T-Cells
  9.1.4 The Use of CMV as a Vaccine Vector
  9.1.5 The Effectiveness of the Vaccine in Humans
  9.1.6 The Pre-Exposure Prophylactic Use of Anti-Retroviral Drugs as an Alternative Strategy
  9.1.7 The Timeline for a Human Trial of the Vaccine

10. CONCLUSIONS

10.1 The Vaccine Market Will Show Strong Growth Through to 2022
10.2 Therapeutic Vaccines Will Increase Market Share
10.3 Prevnar-13
10.4 The Vaccine Pipeline is Strong
10.5 Concluding Remarks

LIST OF TABLES

Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD - Present
Table 3.1 World Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 3.2 World Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 3.3 World Vaccines Market Segments: Revenues ($bn), Overall Market Shares (%), 2011
Table 3.4 World Vaccines Market Segments: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 3.5 World Vaccines Market Segments: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 3.6 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
Table 3.7 Leading Regions in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
Table 3.8 World Vaccines Market Regions: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 3.9 World Vaccines Market Regions: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 3.10 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 3.11 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2022
Table 3.12 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 3.13 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2022
Table 4.1 Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 4.2 Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 4.3 Leading Products in the Paediatric Vaccines Market: Revenues ($bn), Market Shares (%), 2011
Table 4.4 Leading Products in the Pneumococcal Vaccines Market: Revenues ($bn), Market Shares (%), 2011
Table 4.5 Pipeline Pneumococcal Vaccines, 2012
Table 4.6 Prevnar-13: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 4.7 Prevnar-13: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 4.8 Pipeline Paediatric Combination Vaccines, 2012
Table 4.9 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 4.10 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 4.11 ProQuad /MMR-II/Varivax Revenues ($bn), 2009-2011
Table 4.12 ProQuad/MMR-II/Varivax: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 4.13 ProQuad/MMR-II/Varivax: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 4.14 Infanrix/Pediarix/Others Revenues ($bn), AGR (%), Share of Total (%), by Region, 2011
Table 4.15 Infanrix/Pediarix/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 4.16 Infanrix/Pediarix/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 4.17 RotaTeq: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 4.18 RotaTeq: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 4.19 Other Paediatric Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 4.20 Other Paediatric Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 4.21 Selected Late-Stage Paediatric Vaccines Pipeline, 2012
Table 4.22 Selected Phase I and Phase II Paediatric Vaccines Pipeline, 2012
Table 4.23 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 4.24 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 5.1 Influenza Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 5.2 Influenza Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 5.3 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 5.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 5.5 Fluarix/Flulaval: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 5.6 Fluarix/Flulaval: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 5.7 Selected Products in the Influenza Vaccines Pipeline, 2012
Table 5.8 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 5.9 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 6.1 Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 6.2 Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 6.3 Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), Market Shares (%), 2011
Table 6.4 Pipeline HPV Vaccines, 2012
Table 6.5 Gardasil: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 6.6 Gardasil: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 6.7 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 6.8 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 6.9 Cervarix: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 6.10 Cervarix: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 6.11 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 6.12 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 6.13 Adacel and Other Adult Boosters: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 6.14 Adacel and Other Adult Boosters: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 6.15 Other Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 6.16 Other Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 6.17 Selected Late-Stage Adult Prophylactic Vaccines Pipeline, 2012
Table 6.18 Selected Prophylactic Anthrax Vaccines Pipeline, 2012
Table 6.19 Selected Prophylactic Dengue Fever Vaccines Pipeline, 2012
Table 6.20 Selected Prophylactic Hepatitis Vaccines Pipeline, 2012
Table 6.21 Selected Prophylactic Malaria Vaccines Pipeline, 2012
Table 6.22 Selected Prophylactic Ebola Virus Vaccines Pipeline, 2012
Table 6.23 Selected Prophylactic Cytomegalovirus Vaccines Pipeline, 2012
Table 6.24 Selected Prophylactic Streptococcal Vaccines Pipeline, 2012
Table 6.25 Selected Prophylactic Staphylococcal Vaccines Pipeline, 2012
Table 6.26 Selected Other Adult Prophylactic Vaccines in Development, 2012
Table 6.27 Selected Other Adult Prophylactic Vaccines in Phase I Development, 2012
Table 6.28 Selected Prophylactic HIV Vaccines Pipeline, 2012
Table 6.29 Selected Prophylactic HIV Vaccines Phase I Pipeline, 2012
Table 6.30 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 6.31 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 7.1 Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 7.2 Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 7.3 Provenge: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 7.4 Provenge: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 7.5 Therapeutic Cancer Vaccines: Late-Stage Pipeline, 2012
Table 7.6 Therapeutic Cancer Vaccines: Selected Pipeline Products, 2012
Table 7.7 Therapeutic Allergy Vaccines: Selected Pipeline Products, 2012
Table 7.8 Therapeutic Addiction Vaccines: Selected Pipeline Products, 2012
Table 7.9 Therapeutic Chronic Infectious Disease Vaccines: Selected Pipeline Products, 2012
Table 7.10 Therapeutic Vaccines for Other Chronic Diseases: Selected Pipeline Products, 2012
Table 7.11 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 7.12 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
Table 10.1 Selected Vaccines in Late-Stage Development, 2012

LIST OF FIGURES

Figure 3.1 World Vaccines Market: Revenues ($bn), 2011-2022
Figure 3.2 World Vaccines Market Segments: Revenues ($bn), Overall Market Shares (%), 2011
Figure 3.3 World Vaccines Market Segments: Revenues ($bn), 2011-2022
Figure 3.4 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
Figure 3.5 Leading Regions in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
Figure 3.6 World Vaccines Market Regions: Revenues ($bn), 2011-2022
Figure 3.7 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), 2011-2022
Figure 3.8 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), 2011-2022
Figure 4.1 Paediatric Vaccines Market: Revenues ($bn), 2011-2022
Figure 4.2 Drivers and Restraints for Paediatric Vaccines, 2012
Figure 4.3 Leading Products in the Paediatric Vaccines Market: Revenues ($bn), Market Shares (%), 2011
Figure 4.4 Drivers and Restraints for Prevnar-13, 2012
Figure 4.5 Leading Products in the Paediatric Pneumococcal Vaccines Market: Revenues ($bn), Market Shares (%), 2011
Figure 4.6 Prevnar-13: Revenues ($bn), 2011-2022
Figure 4.7 Drivers and Restraints for Pentacel/Pediacel/Pentaxim/Others, 2012
Figure 4.8 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), 2011-2022
Figure 4.9 ProQuad /MMR-II/Varivax Revenues ($bn), 2009-2011
Figure 4.10 Drivers and Restraints for ProQuad/MMR-II/Varivax, 2012
Figure 4.11 ProQuad/MMR-II/Varivax: Revenues ($bn), 2011-2022
Figure 4.12 Infanrix/Pediarix/Others Revenues ($bn) by Region, 2011
Figure 4.13 Drivers and Restraints for Infanrix/Pediarix/Others, 2012
Figure 4.14 Infanrix/Pediarix/Others: Revenues ($bn), 2011-2022
Figure 4.15 Division of the Rotavirus Vaccine Market, 2011
Figure 4.16 Drivers and Restraints for RotaTeq, 2012
Figure 4.17 RotaTeq: Revenues ($bn), 2011-2022
Figure 4.18 Other Paediatric Vaccines: Revenues, 2011-2022
Figure 4.19 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), 2011-2022
Figure 5.1 Influenza Vaccines: Revenues ($bn), 2011-2022
Figure 5.2 Drivers and Restraints for Influenza Vaccines, 2012
Figure 5.3 Drivers and Restraints for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2012
Figure 5.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), 2011-2022
Figure 5.5 Drivers and Restraints for Fluarix/Flulaval, 2012
Figure 5.6 Fluarix/Flulaval: Revenues ($bn), 2011-2022
Figure 5.7 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), 2011-2022
Figure 6.1 Adult Prophylactic Vaccines: Revenues ($bn), 2011-2022
Figure 6.2 Drivers and Restraints for Adult Prophylactic Vaccines, 2012
Figure 6.3 Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), Market Shares (%), 2011
Figure 6.4 Drivers and Restraints for Gardasil, 2012
Figure 6.5 Gardasil: Revenues ($bn), 2011-2022
Figure 6.6 Chronic Hepatitis B: Global Prevalence by Region, 2012
Figure 6.7 Drivers and Restraints for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012
Figure 6.8 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), 2011-2022
Figure 6.9 HPV Vaccine Market Shares (%), 2011
Figure 6.10 Cervarix Sales by Region (%), 2011
Figure 6.11 Drivers and Restraints for Cervarix, 2012
Figure 6.12 Cervarix: Revenues ($bn), 2011-2022
Figure 6.13 Drivers and Restraints for Menactra and Other Meningitis/Pneumonia Vaccines, 2012
Figure 6.14 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), 2011-2022
Figure 6.15 Adult Booster Market Shares (%), 2011
Figure 6.16 Drivers and Restraints for Adacel and Other Adult Boosters, 2012
Figure 6.17 Adacel and Other Adult Boosters: Revenues ($bn), 2011-2022
Figure 6.18 Other Adult Prophylactic Vaccines: Revenues ($bn), 2011-2022
Figure 6.19 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), 2011-2022
Figure 7.1 Therapeutic Vaccines Market: Revenues ($bn), 2011-2022
Figure 7.2 Drivers and Restraints for Therapeutic Vaccines, 2012
Figure 7.3 Drivers and Restraints for Provenge, 2012
Figure 7.4 Provenge: Revenues ($bn), 2011-2022
Figure 7.5 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), 2011-2022
Figure 10.1 Vaccine World Market Revenues ($bn), 2011-2016
Figure 10.2 Vaccine World Market Revenues ($bn), 2017-2022
Figure 10.3 Vaccine World Market Segments: Revenues ($bn), 2011-2016
Figure 10.4 Vaccine World Market Segments: Revenues ($bn), 2017-2022
Figure 10.5 Leading 10 Vaccine Franchises of 2011: Revenues ($bn), 2011-2022

COMPANIES LISTED

Aaron Diamond AIDS Research Center
Abbott Laboratories
Acambis
ACE Biosciences
Activartis Biotech
Adamis Pharmaceuticals
Aduro BioTech
Advaxis
Aerus Global TB Vaccine Foundation
Affiris
Agenus
Akela Pharma
ALK Abello
Allergy Therapeutics
Allertein Therapeutics
AlphaVax
Antigen Express
Antigenics
Aphton
Argos Therapeutics
Astellas Pharma US
AstraZeneca
AuRx
AVAX Technologies
Avant Immunotherapeutics
Baxter Healthcare
Bayer HealthCare
Bayhill Therapeutics
Bellicum Pharmaceuticals
Bharat Biotech
Biken Japan
Biogen Idec
Bill & Melinda Gates Foundation
Biomira
Bionor Pharma
BioSante Pharmaceuticals
Biotech Synergy
Biovest International
BN ImmunoTherapeutics (Bavarian Nordic)
Cancer Advances
CancerVax
Cell Control
Celldex Therapeutics
Cell Genesys
Celltech
CEL-SCI
Celtic Pharma
Centers for Disease Control and Prevention (CDC)
CG Therapeutics
Chemo-Sero-Therapeutic Research Institute
Chiron
Colby Pharmaceutical
Coley Pharmaceuticals
Corixa
Cosmo Pharmaceuticals
Crucell
CSL Behring
Cytokine PharmaSciences
Cytos Biotechnology
DBV Technologies
Dendreon
Denka Seiken
Department of Defense (US)
Dynavax Technologies
DynPort Vaccine
EMD Serono
Emergent BioSolutions
Endocyte
Epeius Biotechnologies
Etubics
European Medicines Agency (EMEA/EMA)
Evans Medica
Favrille
Food and Drug Administration (US FDA)
Galena Biopharma
GeneCure Biotechnologies
Genentech
Genetic Immunity
Genitope
GenPhar
GenVec
GeoVax Labs
Geron
GlaxoSmithKline (GSK)
GlobeImmune
Gradalis
Greer Laboratories
Hawaii Biotech
Heat Biologics
iBio
Ichor Medical Systems
immatics biotechnologies
Immunitor
ImmunoCellular Therapeutics
Immunocore
Immunofrontier
Immunotope
Immunovaccine
Infectious Diseases Research Institute
Inovio Pharmaceuticals
Institut Pasteur
Intercell
Intercell USA
International Vaccine Institute
Intracel
Inviragen
Janssen Alzheimer Immunotherapy
JN-International Medical
Johns Hopkins University
KAEL-GemVax
Kitasato Institute
LigoCyte Pharmaceuticals
Liquidia Technologies
Ludwig Institute for Cancer Research
MabVax Therapeutics
MaxCyte
Medeva
Medicago USA
MedImmune
Medirace
Memgen
Menarini
Merck & Co.
Merck KGaA
Meridian Biosciences
Momotaro-Gene
Nabi Biopharmaceuticals
NanoBio
Nanotherapeutics
National Institutes of Health (NIH, US)
Neurological Disorders
NewLink Genetics
Northwest Biotherapeutics
Novadigm Therapeutics
Novartis
NovaRx
Novavax
Novo Energies
NuVax Therapeutics
Okairos
Oncothyreon
OncoVax
Opal Therapeutics
Optimer Pharmaceuticals
Orban Biotech
Oxford BioMedica
PaxVax
Pfizer
PharmAthene
Pique Therapeutics
Polynoma
Powderject
Prima Biomed
Profectus Biosciences
Progenics Pharmaceuticals
Protein Sciences
Quantum Immunologics
Quest PharmaTech
Roche
Sabin Vaccine Institute
Sanaria
Sanofi
Sanofi Pasteur
Selecta Biosciences
Sinovac
Soligenix
Stallergenes
Stemline Therapeutics
Takeda
Teva Pharmaceutical Industries
The GAVI Alliance
Theraclone Sciences
Thymon
Transgene
TVAX Biomedical
UNICEF
United Biomedical
University of Queensland
University Hospital of Tubingen
US Naval Medical Research Center
Vaccine Research Center (NIAID)
Vaccine Technologies
Vaccinogen
Vaxart
VaxGen
Vaxin
VaxInnate
VaxOnco
Vical
WHO (World Health Organization)
Xcellerex
Skip to top


Ask Your Question

World Vaccines Market 2012-2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: